Page last updated: 2024-10-26

dipyridamole and Dysphagia

dipyridamole has been researched along with Dysphagia in 1 studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Research Excerpts

ExcerptRelevanceReference
"Many stroke survivors have severe dysphagia and are unable to take antithrombotic medications orally."2.75Pharmacokinetics of extended-release dipyridamole following administration through a gastrostomy tube: an open-label, case-control, two-centre study. ( Batista, LM; Crandell, D; Greer, DM; Lima, FO, 2010)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Batista, LM1
Crandell, D1
Lima, FO1
Greer, DM1

Trials

1 trial available for dipyridamole and Dysphagia

ArticleYear
Pharmacokinetics of extended-release dipyridamole following administration through a gastrostomy tube: an open-label, case-control, two-centre study.
    Clinical drug investigation, 2010, Volume: 30, Issue:7

    Topics: Aged; Aggrecans; Case-Control Studies; Cerebral Infarction; Deglutition Disorders; Delayed-Action Pr

2010